Cite
HARVARD Citation
Ridker, P. et al. (2017). Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 390 (10105), pp. 1833-1842. [Online].